William Blair analyst Andy Hsieh has maintained their bullish stance on VKTX stock, giving a Buy rating today.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Andy Hsieh has given his Buy rating due to a combination of factors, including promising new data from Viking Therapeutics’ VK2735 trials. The Phase II VENTURE trial and the upcoming Phase III VANQUISH-1 trial highlight the potential cardiometabolic benefits of VK2735, a GLP-1/GIP dual receptor agonist, in treating obesity. The Phase III trial’s unique 2-week titration period is expected to enhance tolerability by reducing gastrointestinal side effects.
Additionally, Viking Therapeutics’ obesity franchise is seen as highly attractive to big pharmaceutical companies, especially in light of recent industry interest in mergers and acquisitions. The potential of VK2735, along with the dual amylin and calcitonin receptor agonist program, provides multiple opportunities for growth. The interest in the direct-to-consumer market further supports the positive outlook, making Viking Therapeutics a top pick for future investment.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $102.00 price target.